Research programme: bispecific antibody therapeutics - Merus

Drug Profile

Research programme: bispecific antibody therapeutics - Merus

Alternative Names: MCLA-114; MCLA-122; MCLA-134; MCLA-158

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merus
  • Developer Merus; ProBioGen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD3 antigen modulators; Epidermal growth factor modulators; ERBB-3 receptor modulators; G protein-coupled receptor modulators; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours
  • Research Multiple myeloma

Most Recent Events

  • 30 Nov 2017 Merus announces intention to submit Clinical Trial Application (CTA) for planned phase I/II trial of MCLA 158 in Colorectal cancer by the end of 2017
  • 19 Sep 2017 Merus has patent protection for Biclonics® technology in USA
  • 22 Aug 2017 Merus has patent protection for Biclonics® technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top